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Purpose: It was proposed that total thiols (tSH) as powerful reducing agents and oxidized low-density lipoprotein (OX-
LDL) may be associated with development of choroidal neovascularization in exudative age-related macular degeneration
(E-ARMD).
Methods: In a case-control study, 45 patients with E-ARMD were compared with 45 sex- and age-matched healthy
controls. The levels of plasma homocysteine (Hcy) and OX-LDL as oxidant agents, and of tSH and glutathione (GSH) as
antioxidant markers, were estimated in E-ARMD patients and controls.
Results: The levels of Hcy (15.4±7.2 μM versus 10.7±3.7 μM; p=0.001) and OX-LDL (52.2±13.8 U/l versus 37.8±10.8
U/l; p=0.001) were statistically higher, while GSH (1.10±0.97 μM versus 2.09±1.04 μM; p=0.001) and tSH (0.31±0.06
mM versus 0.35±0.05 mM; p=0.001) were statistically lower, in the patients with E-ARMD than in the control group,
respectively. The plasma OX-LDL concentration also exhibited a positive and significant correlation with Hcy (r=0.719,
p=0.001) in patients with E-ARMD.
Conclusions: Lower GSH and tSH as antioxidant and higher Hcy levels as oxidant agents in E-ARMD patients may have
resulted in an oxidative environment that was associated with OX-LDL. Further studies with more cases are required to
confirm the hypothesis.
Age-related macular degeneration (ARMD) is one of the
leading causes of blindness among the elderly throughout the
world [1]. It is a complex, multifactorial disease that affects
the central region of the retina. The prevalence of early ARMD
increases from around 4% in those younger than 60 years to
more than 30% in those 85 years and older [2]. There are two
forms of ARMD, nonexudative (dry) and exudative (wet). The
nonexudative form is more common, and accounts for most
ARMD cases. The exudative form (E-ARMD), however, is
more debilitating, and is responsible for more than 80% of the
visual loss in such patients. New choroidal vessel formation,
vascular leakage, and hemorrhage are the hallmarks of E-
ARMD [3]. It is also associated with degenerative, oxidative,
and inflammatory changes in the macular region of the retina.
Genetic factors, oxidative stress, ischemia, aging of the retinal
pigment epithelium, and inflammation are believed to be the
main etiological factors of E-ARMD [4]. In recent genetic
investigations, Hageman et al. reported that a variation in the
factor H gene increases the likelihood of developing ARMD
[5]. There are genetic predisposing factors, but these do not
fully account for the mechanism of the disease. These genetic
factors may modify the severity of the ARMD phenotype.
Oxidative  stress  is  among  the  modifiers  that  can  lead  to
changes in the structure of the macular region [6].
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There is good evidence that oxidative stress is involved
in the pathogenesis of ARMD [7]. Oxidative stress results in
the generation of free radicals, leading to the promotion of
lipid  peroxidation.  This  affects  not  only  low  density
lipoprotein (LDL) and other lipoproteins, but also cellular
lipids, including those in arterial walls and macrophages [8].
Increases in oxidative products contribute to atherosclerosis
and vasomotor tone. Vine et al. showed that elevated CRP and
homocysteine levels are associated with ARMD and that they
contribute  to  inflammation  and  atherosclerosis  in  the
pathogenesis of ARMD [9]. Essentially, retinal hypoxia and
cumulative  oxidative  stress  contribute  to  aging  processes
(e.g., reduced ability for cell division and altered enzyme
activity).  The  hypoxia  of  retinal  cells  then  induces  the
formation of the vascular endothelial growth factor. Vascular
and oxidative stress theories have been implicated for the
development  of  choroidal  neovascularization  in  E-ARMD
[10,11].
Thiols are powerful reducing agents that are capable of
acting as antioxidants in vivo. Thiols exist in three forms: free-
thiol and two types of disulfides, namely, homodisulfides and
heterodisulfides.  Several  aminothiols,  e.g.,  cysteine,
homocysteine (Hcy), and glutathione (GSH), and disulfides
(e.g.,  cystine,  homocystine,  and  oxidized  glutathione),
interact by means of redox and disulfide exchange [12]. This
dynamic system (with respect to thiol status) is important for
normal physiologic function [13]. Changes in the redox thiol
status lead to the induction of oxidative stress and apoptosis.
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2578As both an intracellular and extracellular redox buffer, tSH
plays  important  roles  in  the  in  vivo  prevention  of
atherosclerosis [14].
Hcy, an amino acid that is found in the blood, is an
independent and potentially modifiable risk factor for various
forms  of  vascular  disease.  Epidemiological  studies  have
reported that the level of Hcy in blood is related to higher risk
of  coronary  heart  disease,  stroke,  and  peripheral  vascular
disease. Other evidence suggests that Hcy may have an effect
on atherosclerosis by damaging the inner lining of arteries and
promoting blood clots [15,16]. The Hcy concentration in the
blood of healthy individuals varies with age, geographical
area, and genetic factors; its concentration normally increases
with age [17].
The adverse effects of Hcy on endothelial function may
be mediated by (1) the reduced production and bioavailability
of nitric oxide as a result of oxidant stress [18], with the
formation  of  reactive  oxygen  species  [19],  including
superoxide  anion  and  hydrogen  peroxide,  increased  lipid
peroxidation [20], (2) impaired production of the antioxidant
glutathione peroxidase [21] and (3) more important by its
metabolite, homocysteinethiolacton. Coral et al. [22]. showed
that Hcy is a well known inducer of the vascular endothelial
cell damage associated with extracellular matrix changes and
increased collagen turnover
The cellular uptake of oxidized low-density lipoprotein
(OX-LDL) by macrophages and vascular endothelial cells
plays a crucial role in the pathogenesis of atherosclerosis
[21]. Because the pathologic changes in E-ARMD are similar
to  those  in  atherosclerosis  [23,24],  and  because
atherosclerosis  may  contribute  to  the  pathogenesis  of  E-
ARMD [25,26], we hypothesized that oxidized lipoproteins
in the macular area of eyes with E-ARMD may be improved,
just as is intima in cases with atherosclerosis that is detectable
by OX-LDL levels in blood.
Because  a  relationship  exists  between  hyper-
homocysteinemia and atherosclerotic disease, we designed
this study to evaluate the total levels in plasma of Hcy and
OX-LDL acting as oxidant agents, as well as levels of other
related physiologic thiol compounds acting as antioxidant
markers in E-ARMD.
METHODS
Study population: This case-control study was conducted in
the  Retina  clinic  (Department  of  Ophthalmology,  Tabriz
University  of  Medical  Sciences),  between  June  2008  and
January  2009.  The  study  groups  were  composed  of  90
individuals ranging in age between 50 and 80 years, enrolling
45 patients with E-ARMD (18 men and 27 women; mean age:
71±7 years) and 45 healthy matched controls (18 men and 27
women; mean age: 69±5 years). Data regarding age and sex,
and a detailed medical history, were recorded. All participants
underwent a complete ophthalmic examination consisting of
the  best  corrected  visual  acuity  (using  Snellen-Chart  and
calculated as the logarithm of the minimal angle of resolution,
notated  “logMAR”),  slit-lamp  biomicroscopy,  dilated
funduscopy (using a Slit-lamp, Haag-Streit, R 900; Haag-
Streit  AG,  Switzerland  with  a  super-field  indirect  lens),
fundus  photography,  and  fundus  fluorescein  angiography
(Imagenet 2000; Topcon TRC 50IX; Topcon Corp., Japan)
when necessary. Recruited patients in the study had either a
classic form of choroidal neovascularization or a disciform
scar. To limit the effects of interference factors in our results,
we excluded other pathological ophthalmic conditions, such
as trauma and angle-closure glaucoma. We also excluded
those who were in an oxidative condition, such as smokers,
subjects who were on antioxidant supplements, and subjects
with systemic disorders such as diabetes, any inflammatory
processes, and renal and/or liver dysfunction.
The ethics committee at the Tabriz University of Medical
Sciences  reviewed  and  approved  the  present  study,  in
compliance  with  the  Declaration  of  Helsinki.  Informed
consent was obtained from all participants.
Sampling  and  primary  tests:  Participants’  venous  blood
samples  were  obtained  the  morning  following  overnight
fasting. The sera or plasma were separated immediately and
then  analyzed  using  enzymatic  assays  with  an  automated
chemical analyzer (Abbott Analyzer; Abbott Laboratories,
Abbot Park, IL) for serum glucose, urea, creatinine, alanine
aminotransferase,  aspartate  aminotransferase.  Serum  lipid
profiles, including total cholesterol, triglycerides, and high-
density  lipoprotein  (HDL)  cholesterol.  Low-density
lipoprotein  (LDL)  cholesterol  was  calculated  using  the
Friedewald equation [27]. The remaining samples were stored
at −70 °C pending analysis.
Homocysteine: Plasma Hcy concentrations were determined
using a commercially available enzyme-linked immunoassay
(Axis-Shield, Axis Biochemical ASA, Distributed by IBL,
Hamburg, Germany). With this method, total free and protein-
bound circulating Hcy moieties are reduced to free Hcy with
dithiothreitol. The Hcy was then converted to S-adenosyl-L-
homocysteine (SAH) by using SAH hydrolase and excess
adenosine. After the addition of an anti-SAH antibody, in the
next  stage,  a  secondary  rabbit  anti-mouse  antibody  was
labeled  with  the  enzyme  horseradish  peroxidase.  The
peroxidase  activity  was  measured  spectrophotometrically
after  the  addition  of  the  substrate.  The  absorbance  was
inversely related to the concentration of Hcy in the sample.
Total  thiol  levels  in  plasma:  Plasma  tSH  levels  were
determined using a spectrophotometric method, as previously
described by Hu [28].
Glutathione: Plasma GSH levels were measured using an
Enzyme  immune  assay  (EIA)  method  (Cayman  Chemical
Company, Ann Arbor, MI).
Oxidized  low  density  lipoprotein:  Plasma  OX-LDL  levels
were measured using an enzyme-linked immunosorbent assay
(ELISA) kit (Mercodia, Uppsala, Sweden).
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statistical package for the social sciences (SPSS) for Windows
(Version 16, SPSS, Inc., Chicago, IL). The Kolmogorov–
Smirnov test was used to evaluate the distributions, and results
were  expressed  as  means±standard  deviation.  The
independent t-test was used to assess the significance of the
differences between the two groups. The correlations between
OX-LDL and Hcy were evaluated using the Pearson test;
p<0.05 was considered statistically significant.
RESULTS
The  table  summarizes  the  clinical  characteristics  and
laboratory findings from the patients with E-ARMD and from
the controls. Both groups were matched with regard to age and
gender.  As  shown  in  the  Table  1,  the  total  plasma  Hcy
concentration  was  significantly  higher  (71%)  among  the
patients  with  E-ARMD  than  among  the  controls
(15.4±7.2 μM versus 10.7±3.7 μM; p=0.001). The plasma
levels of GSH were significantly lower: almost 50% lower in
the  patients  with  E-ARMD  (1.10±0.97  μM)  than  in  the
controls (2.09±1.04 μM; p=0.001). The differences between
the plasma tSH levels for patients with E-ARMD and the
controls  were  significant  (0.31±0.06  mM  versus
0.35±0.05 mM; p=0.001, respectively). The total plasma OX-
LDL level in the patients with E-ARMD was 40.5% higher
than  the  controls  (52.2  ±  13.8  U/l  versus  37.8±10.8  U/l;
p=0.001).  The  plasma  OX-LDL  concentration  had  a
significant positive correlation with Hcy (r=0.719, p=0.001,
Figure 1) in the patients with E-ARMD, but not in the controls
(r=0.123, p=0.422, Figure 2).
Figure 1. Plasma concentrations of oxidized low-density lipoprotein
(oxidized LDL) versus homocysteine levels in the patient subjects.
There was a direct linear correlation between the oxidized LDL and
homocysteine levels in the patient group (r=0.719, p=0.001).
DISCUSSION
Macula is particularly susceptible to oxidative stress because
of the high number of poly unsaturated fatty acids (PUFAs)
in its cell membranes, its exposure to direct light, and its high
consumption of oxygen [29]. As a result, the macula is highly
susceptible to ROS. Formation of ROS could lead to lipid
peroxidation, which initiates an inflammatory response [30].
Consequently, increased plasma OX-LDL as an oxidant agent
may suggest the presence or risk of ARMD more precisely
than other serum factors. Oxidative stress disrupts the retinal
pigmented epithelial (RPE) cell junctions and the integrity of
the  blood-retina  barrier,  both  of  which  contribute  to
neovascular  processes.  Thus,  oxidative  stress  should  be
considered a risk factor for new vessel formation [31,32].
The main findings of this case-control study was that
higher levels of Hcy as an oxidant agent and lower GSH and
tSH concentrations as antioxidative markers were detected
among the patients with E-ARMD, compared with age- and
gender-matched healthy controls. These results are confirmed
by Coral et al.’s outcomes in a study on exudative ARMD
patients. They revealed that there was a significant, elevated
Hcy level and diminished thiol pool content in E-ARMD
[33]. Many studies have shown that the redox states of human
plasma thiol compounds can transform into oxidized states in
older  age  groups  [34].  tSH  plays  a  prominent  role  in
antioxidant  reactions,  and  in  catalysis,  regulation,  and
electron-transport reactions, and in reactions that preserve the
correct structure of proteins. Mixed disulfides with proteins
are formed by reaction of S-thiolation, in which protein thiols
conjugate with non-protein thiols [35]. This process plays a
regulatory and an antioxidant role, since it protects protein
Figure 2. Plasma concentrations of oxidized low-density lipoprotein
(oxidized  LDL)  versus  homocysteine  levels  in  control  subjects
(r=0.123, p=0.422).
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−SO3H; moreover, it participates in signal transduction [36].
Patients in our study had mild hyperhomocysteinemia, a
state has been described in a study on the Iranian population
by Ghaedi et al. [37]. In that study, the reference intervals for
plasma Hcy were determined. The Hcy means in cases and
controls were 15.56±6.77 and 11.51±4.63, respectively. The
plasma level of Hcy in the 100 normal individuals had a mean
of 11.51, and the 95 percentile of cases were in the ranged of
7.8  to  16.1.  Cross-sectional  and  prospective  studies  have
shown that even mildly increased blood Hcy levels may play
a role as an oxidative agent, linked with an increased risk of
cardiovascular  disease  [38].  Wotherspoon  et  al.  [39]
suggested that hyperhomocysteinaemia might cause vascular
damage by increased oxidant stress and mechanisms other
than endothelial dysfunction. Impaired endothelial function
has  been  demonstrated  in  healthy  subjects  with  mild  to
moderate fasting hyperhomocysteinaemia. Kamburoglu et al.
revealed increased plasma Hcy levels in both the exudative
and dry subtypes of ARMD, and decreased vitamin B12 levels
in  exudative  ARMD.  They  also  suggested  an  association
between  elevated  plasma  homocysteine  and  ARMD,
regardless of the subtype [40]. In a meta-analysis of 30 studies
and more than 6,000 events, a 25% lower Hcy level was
associated with an 11% lower risk of ischemic heart disease
and a 19% lower risk of stroke [41]. These findings have
potentially important clinical implications, because plasma
homocysteine levels can be safely lowered by 25% with folic
acid, and antioxidants such as vitamins C and E may reduce
vascular risk in these high-risk patients [40].
Hcy has been shown to undergo autoxidation and to lead
to the generation of reactive oxygen species (ROS), such as
the superoxide anion (O2
–) and hydroxyl radical (OH°). These
oxidative  radicals  initiate  the  oxidation  of  LDL-C,  which
induces vascular dysfunction and accelerates atherosclerosis
[42].  Homocysteine  thiolactone,  one  of  several  Hcy
metabolites,  can  also  accelerate  atherogenesis  via
homocysteinylated LDL-C (by attaching to apo-B100), which
may be more susceptible to oxidation than native lipoproteins
[43]. Homocysteinylated LDL-C decreases endothelial Na+,
K+-ATPase  activity,  leading  to  an  intracellular  sodium
overload,  and  a  subsequent  increase  in  calcium  ion
concentrations. A high concentration of intracellular calcium
reduces the production of nitric oxide (NO) and increases the
generation  of  peroxynitrite  (ONOO–),  a  highly  reactive
nitrogen species that is derived from NO and from superoxide
anion radicals [44,45].
In the present study, the oxidant agent OX-LDL’s levels
were  higher  in  the  E-ARMD  patients  than  in  the  healthy
controls. We assumed that the increased plasma OX-LDL
concentration was attributable to the hyperoxidative state in
E-ARMD  patients.  LDL  homocysteinylation  causes  the
overproduction of OX-LDL. Endothelial dysfunction is due
to  the  action  of  OX-LDL,  which  subsequently  causes
atherosclerotic  plaque  development.  Kamei  et  al.  [46]
explained that oxidized lipoproteins and macrophages were
colocalized in ARMD lesions, and that most macrophages in
the  choroidal  neovascularization  membranes  expressed
oxidized lipoprotein-specific scavenger receptors. Because
the  uptake  of  OX-LDL  by  macrophages  via  scavenger
TABLE 1. DEMOGRAPHIC DATA FOR THE E-ARMD PATIENTS AND CONTROLS
Parameters Patients (mean±SD) Controls (mean±SD) p value*
Number /Sex 45/(18M, 27 F) 45/(18M, 27 F) -
Age (year) 71±7 69±5 0.11
BCVAa 1.18±0.36 0.10±0.07 0.001
Pseudophakic 34 29 -
BMIb (Kg/m²) 25.3±3.8 27.3±5.6 0.11
Systolic pressure (mmHg) 129.8±20 124.4±7.2 0.12
Diastolic pressure (mmHg) 77.5±10 82.5±8.1 0.11
Glucose (mg/dl) 88.0±13 85.2±14.9 0.58
Urea (mg/dl) 32.3±7.2 34.3± 6.1 0.16
Creatinine (mg/dl) 1.0±0.2 1.08±0.18 0.14
Triglycerides (mg/dl) 144.5±63.8 153.7±49.5 0.45
Cholesterol (mg/dl) 204.0±39.5 181.1±36.3 0.005
HDL-Cc (mg/dl) 43.1±5.0 44.2±6.3 0.34
LDL-Cd (mg/dl) 131.6±40.2 105.1±35.3 0.001
Homocystein (μM) 15.4±7.2 10.7±3.7 0.001
Gluthation (μM) 1.10±0.97 2.09±1.04 0.001
Total thiol (mM) 0.31±0.06 0.35±0.05 0.001
OX-LDLe (U/l) 52.2±13.8 37.8 ±10.8 0.001
     aBCVA = best corrected visual acuity, bBMI = body mass index, cHDL-C = high-density lipoprotein cholesterol, dLDL-C = low-
     density lipoprotein cholesterol, eOX-LDL = oxidized LDL *Independent-sample T test.
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2581receptors and the accumulation of lipid-laden foam cells in the
arterial intima are key events in early atherogenesis, their
findings suggested that macrophages may also accumulate in
the area of the ARMD, possibly to phagocytose oxidized
lipoproteins  through  scavenger  receptors  [21,24].  The
relationship  between  lipid  peroxidation  and
hyperhomocysteinemia  suggests  that  the  generation  of
reactive intermediates by thiol oxidation may be one of the
most important mechanisms in this context [14].
Maintaining the intracellular thiols, such as GSH, in their
reduced form, may allow for the maintenance of Hcy and other
intracellular thiols in redox states [47]. In this study, low
plasma levels of GSH and thiol were apparent in E-ARMD
patients, compared with healthy individuals. Since the plasma
GSH concentration reflects its levels in various tissues, a
reduced plasma concentration of GSH may be a diagnostic
indicator of a pathological state [48].
GSH is the most important endogenous antioxidant in
humans. It is often accompanying by other endogenous thiols,
such  as  cysteine,  cysteinylglycine  and  even  Hcy  (in  low
concentration). These thiols scavenge ROS and are involved
in preserving the pro-oxidant–antioxidant balance in human
tissues [49]. It has been reported that GSH and thiol content
may decrease in certain pathological states and on account of
the  aging  process.  This  causes  Hcy  oxidation  to  become
uncoupled, which leads to oxidative damage to the endothelial
cells [50]. In fact, several studies have demonstrated that a
high  dietary  intake  of  anti-oxidative  agents,  such  as  beta
carotene, vitamins C and E, and zinc, may be associated with
a substantially reduced risk of E-ARMD in elderly persons
[51]. This effect was also found by the Age-Related Eye
Disease Study Research Group [52-55].
Although thiols protect cells from oxidative stress by
scavenging reactive intermediates, they have ominous side
effects that make their clinical application potentially harmful.
In the presence of metal ions (such as Fe++) and oxygen, they
can  be  autoxidized,  generating  highly  reactive,  partially
reduced oxygen species, such as superoxides and hydrogen
peroxide [49,50]. Thiols may also cause lipid peroxidation,
producing  hydroxyl  radicals  and  cleaving  proteins  via  a
reaction that requires iron [56,57]. In the absence of metal
ions, thiols protect against oxidative stresses.
Jiang et al. [58] indicated that a shift in the extracellular
redox state in vivo could play an important role in RPE cell
function and contribute to apoptosis of RPE cells undergoing
oxidative  stress.  Because  of  this,  the  extracellular  thiol/
disulfide redox state may represent a physiologic environment
in  which  other  oxidative  challenges,  such  as  infection,
activation of the immune system, or other stress conditions,
result in enhanced RPE cell loss and the development of
ARMD.  Consequently,  manipulation  of  the  plasma  thiol-
disulfide redox state to a more reduced level may decrease the
sensitivity  of  the  retina  and  RPE  cells  to  apoptosis  from
oxidative stress. Therefore, regulating the oxidation state of
sulfur-containing amino acids may be an important strategy
for controlling cellular damage and atherosclerotic lesions
[59]. Although it needs further study, antioxidant therapy may
inhibit  vascular  disease  in  patients  who  suffer  from
hyperhomocysteinemia and E-ARMD.
Our study had some limitations. We evaluated only a
small number of subjects; thus, these findings may not be
generalized  to  represent  the  entire  E-ARMD  patients’
population. We found that the OX-LDL level was associated
with the plasma Hcy concentration. However, further work is
required in large, case-control studies to determine the general
applicability  of  our  results,  because  of  the  multifactorial
nature of E-ARMD disease.
Conclusions: In conclusion, this study showed that the
extracellular  thiol  state  may  represent  a  physiologic
environment in which other oxidative challenges, such as
hyperhomocysteinemia or other stress conditions related to
macula condition, result in enhanced RPE cell loss and the
development of ARMD. Change in the plasma thiol/disulfide
redox  state  to  a  more  reduced  level  may  decrease  the
sensitivity  of  the  retina  and  RPE  cells  to  apoptosis  from
oxidative stress. Thiol and glutathione levels in the plasma of
patients at risk for E-ARMD or with early ARMD may be
therapeutically  elevated  to  strengthen  the  antioxidative
capacity of the retina and thus reduce the redox state of the
retina.
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